A major advantage of in vivo imaging by fluorescence tomography is that it enables the study of biological targets and pathways in context and in their natural state. Within a preclinical setting, such imaging allows disease states to be observed and measured non-invasively within the whole animal, bridging the gap between drug discovery and human clinical trials. Specifically, the imaging agents developed in the laboratory for use in fluorescence molecular tomography, are now even being translated into the clinic for human diagnostic applications. Similarly, disease-specific fluorescence markers are finding their way back into basic research in high content screening applications. In this third and final webinar in our cell to well to animal series, we will survey the in vivo imaging landscape and follow the flow of technologies and methodologies between lab and clinic.
Webinar
